Notable Labs Announces Partnership With All4Cure

Notable Labs Announces Partnership With All4Cure

FOSTER CITY, CA and SEATTLE; Oct. 28, 2020 (Business Wire) – Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, and All4Cure, which has built a real world data powered network of patients, clinicians and researchers to dramatically improve outcomes for millions of patients with cancer, today announced their partnership.

Learn More
Emerging Technical and Precision Medicine Approaches for Higher Risk Myelodysplastic Syndromes

Emerging Technical and Precision Medicine Approaches for Higher Risk Myelodysplastic Syndromes

Novel precision medicine approaches such as Notable Labs’ ex vivo DSS identify rational drugs and drug combinations and predict clinical therapeutic responses

Getting the right cancer drugs to the right patients relies on the accurate prediction of clinical response to an ever-increasing array of cancer therapies.

Learn More
Notable Labs Announces Addition of Thomas Bock to Board of Directors

Notable Labs Announces Addition of Thomas Bock to Board of Directors

FOSTER CITY, CA – Oct. 13, 2020 – Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, today announced the addition of Thomas A. Bock to its board of directors.

Learn More
Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms
,

Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms

Precision medicine approaches such as ex vivo drug sensitivity screening (DSS) are appealing to inform rational drug selection in myelodysplastic syndromes (MDSs) and acute myeloid leukemia, given their marked biologic heterogeneity.

Learn More
Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion- positive AML Defines Novel Therapeutic Options – A COG and TARGET Pediatric AML Study
,

Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion- positive AML Defines Novel Therapeutic Options – A COG and TARGET Pediatric AML Study

A cryptic inv(16)(p13.3q24.3) encoding the CBFA2T3-GLIS2 fusion is associated with poor outcome in infants with acute megakaryocytic leukemia. We aimed to broaden our understanding of the pathogenesis of this fusion through transcriptome profiling.

Learn More
×